Neglected Disease Research and Development: Emerging Trends
The seventh G-FINDER survey reports on 2013 global investment into research and development (R&D) of new products for neglected diseases, and identifies trends and patterns across the seven years of global G-FINDER data. In all, 197 organisations completed the survey in 2013, which covered:
- 34 neglected diseases
- 138 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products
- Platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
- All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.
A key change for the 2014 report is that all years’ data is reported in 2013 US dollars (US$), not converted to a 2007 US$ baseline as in previous reports. A further change is that, following a review by our new Advisory Committee (AC), the survey has been expanded to include three additional diseases: cryptococcal meningitis, hepatitis C genotype 4 and leptospirosis. The AC review also identified the increased commercialisation of dengue vaccine R&D. As a result, dengue vaccines no longer fit the criteria for inclusion in the G-FINDER survey, and investments in dengue vaccines were excluded retrospectively. This does not affect other dengue products, which will continue to be included.
Visit the Policy Cures website to learn more about the G-Finder reports.